vincristine / Generic mfg. - LARVOL DELTA

Epcoritamab + R-mini-CHOP results in 2-year remissions and high MRD negativity rates in elderly patients with newly diagnosed DLBCL: Results from the EPCORE NHL-2 trial (ASH 2025) - P1/2 | "Introduction: Dose-attenuated rituximab plus cyclophosphamide, doxorubicin, vincristine, andprednisone (R-mini-CHOP) is a standard of care (SOC) for patients with newly diagnosed (1L) diffuse largeB-cell lymphoma (DLBCL) unable to receive full-dose R-CHOP due to age or comorbidities. Fixed-duration epcoritamab + R-mini-CHOP led to high ORR and CR rates, rapid andsustained MRD negativity, and durable remissions in elderly patients with newly diagnosed DLBCLineligible for full-dose R-CHOP. Despite the elderly population, outcomes compare favorably withhistorical outcomes of R-mini-CHOP alone. These results, along with those from other arms of the trial,support combinations of epcoritamab with SOC across a range of disease settings and patientpopulations."

Clinical • Minimal residual disease • Cardiovascular • Cytomegalovirus Infection • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma

B-Cell Lymphoma Following an Indolent Course Over 30 Years with Immunophenotypic Changes at Each Recurrence. (PubMed, Eur J Case Rep Intern Med) - "Diffuse large B-cell lymphoma (DLBCL) can undergo stepwise immunophenotypic and molecular evolution over decades, progressing from a germinal Center B-cell-like (GCB)-like phenotype to an activated B-cell -like/non-GCB pattern (MUM1+, CD30+) and ultimately to an aggressive anaplastic variant.The cell-of-origin profile and its associated molecular features are not necessarily static; thus, therapeutic strategies for relapsed DLBCL should be tailored to the current disease state rather than relying on the signature at initial diagnosis.Longitudinal re-evaluation through repeat biopsies is imperative to capture the evolving landscape of the malignancy, ensuring that treatment selection is guided by the most recent pathological and molecular findings."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • IRF4 • TNFRSF8

Perforated Small Intestinal Diffuse Large B-Cell Lymphoma Successfully Managed With Surgical Resection and Staged Introduction of Polatuzumab Vedotin-Based Chemotherapy. (PubMed, J Med Cases) - "Polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) is a vincristine-free regimen recently approved for untreated diffuse large B-cell lymphoma (DLBCL). The patient showed an initial tumor reduction without serious gastrointestinal (GI) toxicity. This case suggests that staged introduction of Pola-R-CHP may minimize postoperative GI risk while maintaining safety."

Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

TARGETING ATYPICAL TERATOID/RHABDOID TUMOR: OTS964 SHOWS POTENT CYTOTOXICITY IN BT-12 AND JCRB CELLS (WRMC 2026) - "Current treatment regimens are not standardized and involve some combination of vincristine, carboplatin, etoposide, cyclophosphamide, cisplatin, dactinomycin, and doxorubicin. OTS964 demonstrated strong dose-dependent cytotoxicity against BT-12 and JCRB cells. The results highlight the need for future studies to determine the in vitroefficacy of OTS964 in combination with Navitoclax and Vorinostat, as well as the in vivoefficacy of OTS964 to assess its therapeutic potential in AT/RT cell lines."

Oncology • Rhabdoid Tumor • Sarcoma • CDK1

PRESENTATION OF PATIENT WITH NEUROFIBROMATOSIS I, DUCHENNE MUSCULAR DYSTOPHY, AND GLIOMATOSIS CEREBRI (WRMC 2026) - "He was started on chronic treatment with 5mg/5mL prednisone. We report a case of a 13 year old male who presented at 21 months of age for evaluation of macrocephaly, multiple café-au-lait macules, global developmental delay, and motor delay. The patient was diagnosed with neurofibromatosis type 1 (NF1) with left cervical spine and left hemipelvis plexiform neurofibroma. Despite physical therapy, the patient had persistent generalized hypotonia, more pronounced in his lower extremities."

Clinical • Brain Cancer • Developmental Disorders • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • Neurofibromatosis • Palliative care • Solid Tumor • NF1

RAPID RESPIRATORY RECOVERY FOLLOWING TAFASITAMAB MONOTHERAPY IN A VENTILATOR-DEPENDENT PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (WRMC 2026) - "Case Report: Background: Tafasitamab, a humanized anti-CD19 monoclonal antibody, is FDA-approved in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in patients ineligible for autologous stem cell transplant...The patient had previously completed six cycles of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone) following her initial diagnosis two years prior... This case highlights the potential efficacy of tafasitamab monotherapy in critically ill patients with relapsed DLBCL when combination therapy is not feasible. To our knowledge, this is the first reported case of tafasitamab monotherapy leading to rapid clinical recovery in a ventilator-dependent patient. This report suggests the potential role of tafasitamab monotherapy when oral agents are contraindicated."

Clinical • Monotherapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Interstitial Lung Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Respiratory Diseases

EWING'S SARCOMA DOESN'T STOP AT AMPUTATION: RECURRENT CALCANEAL EWING'S SARCOMA WITH TIBIAL INVOLVEMENT IN AN ADOLESCENT (WRMC 2026) - "The patient underwent three months of induction chemotherapy consisting of ifosfamide, doxorubicin, and vincristine, resulting in a partial response...The tibial recurrence was treated with cyclophosphamide and irinotecan with radiation therapy for local control...This case aims to raise awareness for the need of continued research into prognostic factors and add to the limited existing literature on such cases. Cases like these may aid in the development of novel treatment approaches such as gene therapy or immunotherapy to improve outcomes in patients with rare and aggressive presentations of Ewing's sarcoma."

IO biomarker • Ewing Sarcoma • Gene Therapies • Osteosarcoma • Sarcoma • Solid Tumor • SMARCA4

CONCURRENT CHRONIC MYELOID LEUKEMIA AND OLIGODENDROGLIOMA: A CASE REPORT (WRMC 2026) - "Tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib are first-line in chronic phase...Standard care for grade 2 disease includes radiotherapy (RT) plus procarbazine, lomustine, and vincristine (PCV); temozolomide (TMZ) is an emerging alternative, and recent data support RT plus TMZ in select grade 2 gliomas...Close CBC monitoring and coordinated scheduling reduce toxicity. This report adds to the limited pool of data on dual malignancies and supports structured surveillance during perioperative and chemoradiation periods."

Case report • Clinical • Brain Cancer • Chronic Myeloid Leukemia • Glioma • Hematological Malignancies • Infectious Disease • Leukemia • Movement Disorders • Oligodendroglioma • Solid Tumor • ABL1 • BCR • IDH1

A CASE OF COMPLETE HYDATIDIFORM MOLE COMPLICATED BY DISSEMINATED INTRAVASCULAR COAGULATION, OBSTACLES TO SURGICAL INTERVENTION AND CHEMOTHERAPY (WRMC 2026) - "She was started on EMA/CO (Etoposide, Methotrexate, Actinomycin D/ Cyclophosphamide, Vincristine). However, the treatment course can be complicated by the risk of therapy-induced thrombocytopenia or TMA, as well as potential surgical contraindications. As such, further research will be necessary in the future, and, hopefully, other treatments such as radiation therapy or other medications will be available for GTN."

Clinical • Cardiovascular • Gestational Trophoblastic Neoplasia • Solid Tumor • Thrombocytopenia • Thrombosis

Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) Incorporated to HCVAD Chemotherapy in the Frontline Treatment of Adult Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-ALL/T-LBL) (ASH 2023) - "Pts received 8 cycles (C) of HCVAD (C 1,3, 5, 7) alternating with high dose Ara-C and methotrexate (MTX) (C 2, 4, 6, 8) at approximately 3-week intervals...After the completion of the intensive phase; pts in all cohorts received 30 cycles of maintenance therapy with monthly POMP (prednisone, vincristine, MTX, prednisone) and early intensification with NEL/PEG on C6 and 7 and late intensification with MTX/PEG in C18 and HCVAD on C19... The ongoing phase 2 trial of NEL, ASP, VEN added to the HCVAD regimen shows promising long-term survival in adult pts with T-ALL/LBL with 3-yr OS of 76%-88% in pts treated with HCVAD+NEL+PEG +/- VEN. Larger prospective trials and longer follow-up are needed to demonstrate further benefit."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma. (PubMed, Neuro Oncol) - "R-MPV-A is a highly efficacious and safe regimen with or without LD-WBRT. LD-WBRT contributes to disease control and increases PFS in PCNSL."

Journal • P2 data • Brain Cancer • CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Henan Cancer Hospital | Recruiting ➔ Active, not recruiting

Enrollment closed • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

A CASE REPORT OF MULTI- DRUG COMBINATION THERAPY FOR RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (EBMT 2026) - "The standard first-line treatment for AITL typically involves the CHOP regimen(cyclophosphamide,doxorubicin, vincristine,and prednisone) or CHOP-like protocols... We conducted a single-case retrospective analysis of a 54-year-old male patient with R/R AITL who had progressed following prior treatment with first-line CHOPE (CHOP plus etoposide) and second-line GDP (gemcitabine, doxorubicin liposome and corticosteroid) regimens. After one cycle of chidamide, mitoxantrone, azacitidine and corticosteroid therapy at our linstitution, the original lesions showed significant shrinkage with partial resolution; however, a new lesion emerged, indicating disease progression...The treatment regimen was subsequently modified to a multi-agent combination: chidamide (20 mg twice weekly), decitabine (10 mg d1-5), mitoxantrone liposome (20 mg d2), bevacizumab (600mg day 1), bortezomib (2mg d1, 4, 8) and dexamethasone (20mg d1-4 ), repeated every 21days... Chidamide, a histone deacetylase..."

Case report • Clinical • Combination therapy • IO biomarker • Bone Marrow Transplantation • Immune Modulation • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • CD7

High-Dose Methotrexate Containing Induction Chemotherapy Followed By Nivolumab Consolidation in Older (≥ 65) Patients with Previously Untreated Primary CNS Lymphoma (ASH 2023) - P1 | "Variations of the following regimens were used for induction: 43% R-MPV (rituximab, methotrexate, procarbazine, and vincristine) (43%), 29% MRT (methotrexate, rituximab, and temozolomide), 21% MR (methotrexate and rituximab), and 7% MATRix (methotrexate, cytarabine, thiotepa, and rituximab)... The current study demonstrates encouraging safety and clinical outcomes of nivolumab consolidation in older PCNSL patients who are deemed poor candidates for ASCT or WBI. No DLT was observed during the safety run-in phase, and there was no unexpected toxicity associated with nivolumab although 1 patient discontinued the study treatment due to Stevens-Johnson syndrome, a rare but known AE associated with nivolumab, after Cycle 1. Overall, nivolumab consolidation was associated with favorable survival rates in a group of patients with poor-risk PCNSL."

Clinical • Acute Kidney Injury • CNS Lymphoma • Fatigue • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Central Nervous System Lymphoma • Renal Disease • Septic Shock • Steven-Johnson Syndrome

NCI-2018-02699: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: David Bond, MD | Trial completion date: Dec 2025 ➔ Dec 2026

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (clinicaltrials.gov) - P3 | N=482 | Completed | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Unknown status ➔ Completed

Trial completion • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation (clinicaltrials.gov) - P2 | N=47 | Completed | Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting ➔ Completed

Trial completion • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: University of Rochester | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial primary completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Treatment of metastatic bladder paraganglioma with cadonilimab plus radiotherapy: a case report and literature review. (PubMed, Front Med (Lausanne)) - "The response rate and 5-year overall survival for bladder paraganglioma treated with cyclophosphamide, vincristine, and dacarbazine (CVD) chemotherapy are relatively low...We report, for the first time, a case of metastatic bladder paraganglioma in which a patient treated with cadonilimab in combination with radiotherapy maintained stable disease for 12 months. These results demonstrate that this combination therapy may be a potential treatment option for bladder paraganglioma."

Journal • Neuroendocrine Tumor • Oncology • Pain • Palliative care • Solid Tumor

Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS. (PubMed, J Vis Exp) - "Overall, this micromethod provides a practical, reproducible, and scalable approach for measuring intracellular VCR in primary ALL samples. Its design supports comparative analyses, validation of ex vivo models, and future methodological applications aimed at integrating intracellular drug quantification into broader pharmacological assessments."

Journal • Preclinical • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Response to the Letter to the Editor Entitled "Revisiting Vincristine for FSGS: Proof-of-Mechanism Arrives, but Whom Should we Treat?". (PubMed, Kidney Int Rep) - No abstract available

Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis

Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report. (PubMed, Case Rep Hematol) - "We report the case of a 37-year-old woman with relapsed severe ITP, unresponsive to corticosteroids, IVIG, rituximab, romiplostim, eltrombopag, vincristine, cyclosporine, and splenectomy. This case demonstrates the efficacy of avatrombopag in a patient unresponsive to multiple prior therapies, including other TPO-RAs and splenectomy. Further studies are warranted to determine optimal treatment sequencing and long-term outcomes for patients in this challenging subgroup."

Journal • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: University of Washington | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • T Acute Lymphoblastic Leukemia

First Case of Teclistamab Treatment in a Jehovah's Witness (JW) with Refractory Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "She underwent five cycles of vincristine, doxorubicin, and dexamethasone (VAD) and an autologous stem cell transplant, two years after her diagnosis. She was subsequently treated with thalidomide, bortezomib plus dexamethasone, and later single agent bortezomib...To mitigate immunosuppressive effects, she remained on tocilizumab and prednisone for GCA... This case demonstrates that Teclistamab can be safely and effectively given to a JW patient with refractory MM, without the need for blood transfusions. Despite mild anemia, the patient achieved a positive response with no adverse events like cytokine release syndrome or neurotoxicity. These findings contribute to the growing evidence supporting bloodless management approaches in immunotherapy, providing insights into optimizing care for complex patient populations."

Clinical • Giant Cell Arteritis • Hematological Malignancies • Immunology • Multiple Myeloma • Thrombocytopenia